Table 2:

Overall Survival and Relapse-free Survival Results

Study	Treatment Groups	Consolidation Arms	OS HR (95% CI)	RFS HR (95% CI)
E1910	MRD−	Blin + chemo (n=112) vs chemo (n=112)	0.42 (0.24, 0.75) p = 0.003*	N/A
	MRD+	Blin + chemo (n=40) vs chemo (n=22)	0.40 (0.14, 1.13)	N/A
20120215	High-risk	Blin (n=54) vs chemo (n=57)	0.35 (0.17, 0.70)	0.38 (0.22, 0.66)
AALL1331	High- or intermediate-risk	Blin (n=105) vs chemo (n=103)	0.71 (0.47, 1.08)	N/A
	Low-risk	Blin + chemo (n=127) vs chemo (n=128)	0.46 (0.24, 0.88)	N/A

Source: FDA analysis

Abbreviations: OS: overall survival; RFS: relapse-free survival; MRD: minimal residual disease; Blin: blinatumomab; chemo: chemotherapy

^*Only comparison that met the prespecified criteria for statistical significance